<HashMap><database>biostudies-literature</database><scores/><additional><submitter>Sheridan M</submitter><funding>NIDCR NIH HHS</funding><funding>NIDDK NIH HHS</funding><funding>NCI NIH HHS</funding><funding>National Institutes of Health</funding><pagination>109860</pagination><full_dataset_link>https://www.ebi.ac.uk/biostudies/studies/S-EPMC11108982</full_dataset_link><repository>biostudies-literature</repository><omics_type>Unknown</omics_type><volume>27(6)</volume><pubmed_abstract>Mechanisms by which &lt;i>Porphyromonas gingivalis&lt;/i> (&lt;i>P. gingivalis&lt;/i>) infection enhances oral tumor growth or resistance to cell death remain elusive. Here, we determined that &lt;i>P. gingivalis&lt;/i> infection mediates therapeutic resistance via inhibiting lethal mitophagy in cancer cells and tumors. Mechanistically, &lt;i>P. gingivalis&lt;/i> targets the LC3B-ceramide complex by associating with LC3B via bacterial major fimbriae (FimA) protein, preventing ceramide-dependent mitophagy in response to various therapeutic agents. Moreover, ceramide-mediated mitophagy is induced by Annexin A2 (ANXA2)-ceramide association involving the E142 residue of ANXA2. Inhibition of ANXA2-ceramide-LC3B complex formation by wild-type &lt;i>P. gingivalis&lt;/i> prevented ceramide-dependent mitophagy. Moreover, a FimA</pubmed_abstract><journal>iScience</journal><pubmed_title>Opportunistic pathogen &lt;i>Porphyromonas gingivalis&lt;/i> targets the LC3B-ceramide complex and mediates lethal mitophagy resistance in oral tumors.</pubmed_title><pmcid>PMC11108982</pmcid><funding_grant_id>P30 CA138313</funding_grant_id><funding_grant_id>R01 DE030313</funding_grant_id><funding_grant_id>P30 DK123704</funding_grant_id><pubmed_authors>Engevik M</pubmed_authors><pubmed_authors>Ogretmen B</pubmed_authors><pubmed_authors>Wellslager B</pubmed_authors><pubmed_authors>Sheridan M</pubmed_authors><pubmed_authors>Oleinik N</pubmed_authors><pubmed_authors>Pandruvada S</pubmed_authors><pubmed_authors>Yilmaz O</pubmed_authors><pubmed_authors>Kassir MF</pubmed_authors><pubmed_authors>Lee HG</pubmed_authors><pubmed_authors>Peterson Y</pubmed_authors><pubmed_authors>Szulc ZM</pubmed_authors><pubmed_authors>Chowdhury N</pubmed_authors></additional><is_claimable>false</is_claimable><name>Opportunistic pathogen &lt;i>Porphyromonas gingivalis&lt;/i> targets the LC3B-ceramide complex and mediates lethal mitophagy resistance in oral tumors.</name><description>Mechanisms by which &lt;i>Porphyromonas gingivalis&lt;/i> (&lt;i>P. gingivalis&lt;/i>) infection enhances oral tumor growth or resistance to cell death remain elusive. Here, we determined that &lt;i>P. gingivalis&lt;/i> infection mediates therapeutic resistance via inhibiting lethal mitophagy in cancer cells and tumors. Mechanistically, &lt;i>P. gingivalis&lt;/i> targets the LC3B-ceramide complex by associating with LC3B via bacterial major fimbriae (FimA) protein, preventing ceramide-dependent mitophagy in response to various therapeutic agents. Moreover, ceramide-mediated mitophagy is induced by Annexin A2 (ANXA2)-ceramide association involving the E142 residue of ANXA2. Inhibition of ANXA2-ceramide-LC3B complex formation by wild-type &lt;i>P. gingivalis&lt;/i> prevented ceramide-dependent mitophagy. Moreover, a FimA</description><dates><release>2024-01-01T00:00:00Z</release><publication>2024 Jun</publication><modification>2026-06-01T11:51:36.077Z</modification><creation>2026-04-08T11:59:35.555Z</creation></dates><accession>S-EPMC11108982</accession><cross_references><pubmed>38779482</pubmed><doi>10.1016/j.isci.2024.109860</doi></cross_references></HashMap>